The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Co announces the presentation of preclinical data using antagonists of Toll-like receptor 7 and 9 in mouse models of lupus disease. "The antagonist candidates studied in mouse lupus models have been ...
SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics today announced the initial closing of a $27.4 million Series A financing to advance the development of novel orally-administered, small molecule toll ...
Co announces the presentation of preclinical data using its proprietary antagonists of Toll-like receptors 7 and 9 in mouse models of collagen-induced arthritis, a commonly used model for rheumatoid ...
Innovent Biologics (Suzhou) Co. Ltd. has described antibody-stimulating antibody conjugates (ISACs) comprising antibody targeting folate receptor α (FOLR1; FR-α) or tumor-associated calcium signal ...
An investigational Toll-like receptor (TLR) antagonist was effective in reducing biomarkers and clinical symptoms of systemic lupus erythematosus (SLE) in a pilot trial, evidence that the innate ...
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described Toll-like receptor 7 (TLR7) and/or TLR8 agonists and their immunostimulatory antibody conjugates (ISACs) consisting of antibodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback